Patents by Inventor Suzanne Benedict

Suzanne Benedict has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody formulations and uses thereof
    Patent number: 10195281
    Abstract: The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: February 5, 2019
    Assignee: Tracon Pharmaceuticals, Inc.
    Inventors: Suzanne Benedict, Mark Cornell Manning, Brian M. Murphy, Sharon Real, Charles Theuer
  • Antibody Formulations and Uses Thereof
    Publication number: 20180311359
    Abstract: The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.
    Type: Application
    Filed: July 13, 2018
    Publication date: November 1, 2018
    Inventors: Suzanne Benedict, Mark Cornell Manning, Brian M. Murphy, Sharon Real, Charles Theuer
  • Antibody Formulations and Uses Thereof
    Publication number: 20150209430
    Abstract: The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.
    Type: Application
    Filed: September 5, 2013
    Publication date: July 30, 2015
    Applicant: Tracon Pharmaceuticals, Inc.
    Inventors: Suzanne Benedict, Mark Cornell Manning, Brian M. Murphy, Sharon Real, Charles Theuer
  • Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
    Patent number: 7462713
    Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers. The current invention relates to the making and using of such compounds.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: December 9, 2008
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Eugene Rui, Fen Wang, Yong Wang, Jinjiang Zhu
  • TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY
    Publication number: 20070135415
    Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers. The current invention relates to the making and using of such compounds.
    Type: Application
    Filed: June 23, 2006
    Publication date: June 14, 2007
    Inventors: Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Eugene Rui, Fen Wang, Yong Wang, Jinjiang Zhu
  • Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
    Patent number: 7132533
    Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: November 7, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Eugene Rui, Fen Wang, Yong Wang, Jinjiang Zhu
  • Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
    Publication number: 20060004052
    Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.
    Type: Application
    Filed: July 22, 2005
    Publication date: January 5, 2006
    Inventors: Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Eugene Rui, Fen Wang, Yong Wang, Zinjiang Zhu
  • Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
    Patent number: 6967198
    Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.
    Type: Grant
    Filed: January 9, 2004
    Date of Patent: November 22, 2005
    Assignee: Agouron Pharmaceuticals Inc.
    Inventors: Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Yuanjin Rui, Fen Wang, Yong Wang, Jinjiang Zhu
  • Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
    Publication number: 20050075499
    Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.
    Type: Application
    Filed: January 9, 2004
    Publication date: April 7, 2005
    Inventors: Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Yuanjin Rui, Fen Wang